Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation

NCT02302872 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2021-04-28

No results posted yet for this study

Summary

The objective of the study is to evaluate the safety and performance of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).

Conditions

  • Mitral Valve Regurgitation

Interventions

DEVICE

ARTO System

Sponsors & Collaborators

  • Mvrx, Inc.

    lead INDUSTRY

Principal Investigators

  • Andrejs Erglis, MD · Pauls Stradins Clinical University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2021-07-31
Completion
2021-09-30

Countries

  • Australia
  • France
  • Italy
  • Latvia
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302872 on ClinicalTrials.gov